BiotechTube
Nerai Biosciences

Nerai Biosciences

Zurich, Switzerland· Est.
nerai.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Nerai Biosciences is a private, pre-clinical stage biotech founded in 2021 in Zurich, Switzerland. The company's core innovation is the MORPHEME platform, which integrates high-throughput directed evolution, functional screening, and machine learning to engineer novel CRISPR enzymes with superior specificity and activity. Nerai is advancing a proprietary pipeline of genome editing therapies for rare genetic diseases, with its lead program for Citrullinemia type 1 in in vivo lead optimization. The company is backed by non-dilutive grants and awards, positioning it to address previously inaccessible genetic mutations.

Rare Genetic DiseasesMetabolic DisordersOphthalmology

Technology Platform

MORPHEME: A proprietary platform combining large-scale automated directed evolution, high-throughput cell-based functional screening, and machine learning to engineer novel, highly precise CRISPR genome editors with tailored PAM specificities.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The high unmet need in rare genetic diseases and the curative potential of one-time gene editing therapies create a significant market.
Nerai's platform can generate bespoke editors for previously untargetable mutations, potentially achieving best-in-class precision and opening up new therapeutic areas.
Success with its lead programs could validate the platform for broad partnership opportunities with larger biopharma companies.

Risk Factors

High technical risk associated with novel, pre-clinical genome editors, including potential safety issues like off-target effects and immune responses.
Intense competition from well-funded gene editing companies poses commercial and IP challenges.
The company is pre-revenue and reliant on future fundraising to advance its costly clinical development programs.

Competitive Landscape

Nerai operates in the highly competitive CRISPR therapeutics space, competing against public leaders like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics, as well as large pharma partners. Its key differentiator is the MORPHEME platform's focus on engineering novel, bespoke Cas variants for enhanced precision and expanded target range, aiming to address mutations inaccessible to standard SpCas9-derived editors.

More companies in CRISPR / Gene Editing →More companies in Switzerland →